377.35 USD
↗ 0.00 (0.00%)AT CLOSE (11:59 AM EDT)
Amgen Inc
AMGNNASDAQ • USD
377.83
↗ 0.47 (0.13%)
POST MARKET (AS OF 07:59 PM EDT)
Post Market
AS OF 07:59 PM EDT
377.83
↗ 0.47 (0.13%)
Market: CLOSED
AMGN is currently priced at $377.65. The stock presents a mixed profile: our models indicate a Buy for underlying fundamentals, while technical indicators flash a Strong Sell. Key drivers include a strong Piotroski F-Score of 7/9, exceptional Return on Equity (74.8%) and a bullish Golden Cross on the moving averages. AMGN is fairly valued relative to its sector peers based on current multiples.
Technical & fundamental data as of Sep 11, 2026.
Open?$386.14
High?$386.99
Low?$377.22
Prev. Close?$377.35
Volume?2.3M
Avg. Volume?2.6M
VWAP?$379.46
Rel. Volume?0.87x
Bid / Ask
Bid?$378.00 × 40
Ask?$378.22 × 40
Spread?$0.22
Midpoint?$378.11
Valuation & Ratios
Market Cap?204.0B
Shares Out?540.6M
Float?538.5M
Float %?99.6%
P/E Ratio?23.33
P/B Ratio?17.45
EPS?$16.17
Dividend?2.59%
Ex-Dividend?N/A
News
Profile
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis, which has been further strengthened with the launch of new drugs in blood cancers (Blincyto) and solid tumors (Imdelltra). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
Themes
Employees
31.5K
Market Cap
204.0B
Industry
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Website
Listed
1983-06-17
Address
ONE AMGEN CENTER DRIVE
THOUSAND OAKS, CA 91320
Phone: (805)447-1000
THOUSAND OAKS, CA 91320
Phone: (805)447-1000
Technical OutlookStrong Sell
Strong SellNeutralStrong Buy
Long-Term (Tide)?▼ Bearish(-1/3)
Medium-Term (Wave)?▼ Bearish(-3/3)
Short-Term (Ripple)?▼ Bearish(-3/3)
MA Alignment?Mixed
Full Technical Analysis →Fundamental OutlookBuy
Strong SellNeutralStrong Buy
F-Score?88
Z-Score?37
Momentum?91
Short Sent.?73
Piotroski F-Score?7/9Strong
Altman Z-Score?2.04Grey
Confidence?68%Moderate
Short InterestHigh
Short % of Float?2.41%Low
Short Interest?13.0M
Days to Cover?5.6
Free Float538.5M
Avg Daily Volume2.3M
Settlement Date2026-08-31
Financial Health
Current Ratio?1.37Adequate
Quick Ratio?1.13Adequate
Cash Ratio?0.55Adequate
Debt/Equity?4.90High
ValuationFAIRLY VALUEDvs 10 peers + S&P 500
Score56/100
P/E?23.3FAIR▾
Peers89
S&P53
P/B?17.45HIGH▾
Peers30
S&P9
P/S?5.36FAIR▾
Peers73
S&P26
P/FCF?20.1FAIR▾
Peers70
S&P55
EV/EBITDA?15.4FAIR▾
Peers80
S&P48
EV/Sales?6.49HIGH▾
Peers73
S&P24
Returns & Efficiency
ROE?74.8%STRONG▾
Peers88
S&P95
ROA?9.1%STRONG▾
Peers56
S&P71
Cash Flow & Enterprise
FCF?$10.2B
Enterprise Value?$247.3B
Fundamentals ratios updated end of day